Literature DB >> 22556350

Improvements in the survival of children and adolescents with acute lymphoblastic leukemia.

Jan Cools.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22556350      PMCID： PMC3342961          DOI： 10.3324/haematol.2012.068361

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.

Authors:  Melchior Lauten; Anja Möricke; Rita Beier; Martin Zimmermann; Martin Stanulla; Barbara Meissner; Edelgard Odenwald; Andishe Attarbaschi; Charlotte Niemeyer; Felix Niggli; Hansjörg Riehm; Martin Schrappe
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Genetic and epigenetic studies offer new therapeutic options for the treatment of T-cell acute lymphoblastic leukemia.

Authors:  Jan Cools
Journal:  Haematologica       Date:  2012-03       Impact factor: 9.941

3.  Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome.

Authors:  Lutz Zeidler; Martin Zimmermann; Anja Möricke; Barbara Meissner; Dorothee Bartels; Christoph Tschan; André Schrauder; Gunnar Cario; Lilia Goudeva; Sarah Jäger; Richard Ratei; Wolf-Dieter Ludwig; Andrea Teigler-Schlegel; Julia Skokowa; Rolf Koehler; Claus R Bartram; Hansjörg Riehm; Martin Schrappe; Karl Welte; Martin Stanulla
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

4.  Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.

Authors:  Stephen P Hunger; Xiaomin Lu; Meenakshi Devidas; Bruce M Camitta; Paul S Gaynon; Naomi J Winick; Gregory H Reaman; William L Carroll
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

5.  Outcomes after induction failure in childhood acute lymphoblastic leukemia.

Authors:  Martin Schrappe; Stephen P Hunger; Ching-Hon Pui; Vaskar Saha; Paul S Gaynon; André Baruchel; Valentino Conter; Jacques Otten; Akira Ohara; Anne Birgitta Versluys; Gabriele Escherich; Mats Heyman; Lewis B Silverman; Keizo Horibe; Georg Mann; Bruce M Camitta; Jochen Harbott; Hansjörg Riehm; Sue Richards; Meenakshi Devidas; Martin Zimmermann
Journal:  N Engl J Med       Date:  2012-04-12       Impact factor: 91.245
  5 in total
  4 in total

1.  New opportunities and new problems for acute myeloid leukemia treatment.

Authors:  Idoya Lahortiga; Jan Cools
Journal:  Haematologica       Date:  2012-06       Impact factor: 9.941

2.  Improvement in childhood cancer survival in Lithuania over three decades.

Authors:  Jelena Rascon; Giedrė Smailytė
Journal:  Acta Med Litu       Date:  2020

3.  Default-Mode Network Connectivity Changes Correlate with Attention Deficits in ALL Long-Term Survivors Treated with Radio- and/or Chemotherapy.

Authors:  Federica Mazio; Giuseppina Aloj; Grazia Maria Giovanna Pastorino; Teresa Perillo; Carmela Russo; Maria Pia Riccio; Eugenio Maria Covelli; Rosanna Parasole; Enrico Tedeschi; Lorenzo Ugga; Alessandra D'Amico; Mario Quarantelli
Journal:  Biology (Basel)       Date:  2022-03-24

4.  Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood KMT2A-rearranged Acute Leukemia.

Authors:  Mattias Pilheden; Louise Ahlgren; Axel Hyrenius-Wittsten; Veronica Gonzalez-Pena; Helena Sturesson; Hanne Vibeke Hansen Marquart; Birgitte Lausen; Anders Castor; Cornelis Jan Pronk; Gisela Barbany; Katja Pokrovskaja Tamm; Linda Fogelstrand; Olli Lohi; Ulrika Norén-Nyström; Johanna Asklin; Yilun Chen; Guangchun Song; Michael Walsh; Jing Ma; Jinghui Zhang; Lao H Saal; Charles Gawad; Anna K Hagström-Andersson
Journal:  Hemasphere       Date:  2022-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.